Construction of a recombinant non-mitogenic anti-human CD3 antibody

Hybridoma

Volumn 29, Issue 2, 2010, Pages 115-124

  Hinojosa, Luis E ^a   Hernández, Tays ^a   De Acosta, Cristina Mateo ^a   Montero, Enrique ^a   Pérez, Rolando ^a   López Requena, Alejandro ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CD69 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G1; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY IOR T3; MONOCLONAL ANTIBODY T3Q; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CD3 ANTIGEN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANTIGEN BINDING; ANTIGEN PURIFICATION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOKINE RELEASE; DNA SYNTHESIS; EXPRESSION VECTOR; FLOW CYTOMETRY; GENE AMPLIFICATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HYBRIDOMA; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; CELL PROLIFERATION; GENE VECTOR; IMMUNOLOGY; MOUSE; T LYMPHOCYTE;

MURINAE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD3; CELL PROLIFERATION; GENETIC VECTORS; HUMANS; HYBRIDOMAS; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR; T-LYMPHOCYTES;

EID: 77952019858     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2009.0042     Document Type: Article

References (42)

1. Cosimi AB, Burton RC, Colvin RB, Goldstein G, Delmonico FL, and LaQuaglia MP: Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981;32:535-539.
2. Schroeder TJ, and Hariharan S: First MR: antibody response to OKT3 and methods for monitoring. Transplant Proc 1993;25:77-80.
3. Henell KR, and Norman DJ: Monitoring OKT3 treatment: pharmacodynamic and pharmacokinetic measures. Transplant Proc 1993;25:83-85.
4. Morrison SL, Johnson MJ, Herzenberg LA, and Oi VT: Chimeric human antibody molecules: mouse antigenbinding domains with human constant region domains. Proc Natl Acad Sci USA 1984;81:6851-6855.
5. Riechmann L, Clark M, Waldmann H, and Winter G: Reshaping human antibodies for therapy. Nature 1988;332:323-327.
6. Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, de Pauw L, Wybran J, Kinnaert P, Dupont E, and Toussaint C: Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989;47:606-608.
7. Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, Gevaert Y, Kreis H, Franchimont P, and Bach JF: In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990;49:697-702.
8. Alegre M, Vandenabeele P, Flamand V, Moser M, Leo O, Abramowicz D, Urbain J, Fiers W, and Goldman M: Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor. Eur J Immunol 1990;20:707-710.
9. Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, and Bluestone JA: A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994;57:1537-1543.
10. Norman DJ, Vincenti F, de Mattos AM, Barry JM, Levitt DJ, Wedel NI, Maia M, and Light SE: Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 2000;70:1707-1712.
11. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, and Bluestone JA: A single course of anti-CD3 monoclonal antibody hOKT3gamma1 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-1769.
12. IOR-T3 (CD3 human leukocyte differentiation antigen). Hybridoma 1997;16:588-588.
13. Amador-Perez JF, Ramos M, Artiles V, Suarez O, Garcia M, Taquechel N, Arce S, Alfonzo JP, Moreno D, Cuellar C, Bernaza J, Herrera R, and Lage A: Immunologic monitoring of renal allografted patients treated with the IOR-T3 (anti-CD3) monoclonal antibody. Effects on CD markers and its pharmacokinetics. Inmunología 1994;13:31-36.
14. Ravichandran P, Nataraj T, and Jaganath C: Splenic radiation and double-filtration plasmapheresis in crossmatchpositive live renal transplantation. Transplant Proc 2005;37:1806-1807.
15. Canfield SM, and Morrison SL: The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med 1991;173:1483-1491.
16. Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK, and Zivin RA: In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 2000;200:16-26.
17. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, and Perez R: Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997;3:71-81.
18. Coloma MJ, Hastings A, Wims LA, and Morrison SL: Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods 1992;152:89-104.
19. Sambrook J, Fritsch EF, and Maniatis T: Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989.
20. Sanger F, Nicklen S, and Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977;74:5463-5467.
21. Kammann M, Laufs J, Schell J, and Gronenborn B: Rapid insertional mutagenesis of DNA by polymerase chain reaction (PCR). Nucleic Acids Res 1989;17:5404.
22. Alegre ML, Collins AM, Pulito VL, Brosius RA, Olson WC, Zivin RA, Knowles R, Thistlethwaite JR, Jolliffe LK, and Bluestone JA: Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J Immunol 1992;148:3461-3468.
23. Hirsch R, Bluestone JA, DeNenno L, and Gress RE: Anti-CD3 F (ab') 2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 1990;49:1117-1123.
24. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, and Waldmann H: The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993;23:403-411.
25. Cole MS, Anasetti C, and Tso JY: Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J Immunol 1997;159:3613-3621.
26. Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O'Laughlin R, Peace D, Jollife LK, Haverty T, Bluestone JA, and Thistlethwaite JR Jr: Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1 (Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999;68:608-616.
27. Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T, Krueger J, Martin P, Pavlovic S, Sanders J, Slattery J, Levitt D, Storb R, Woolfrey A, and Anasetti C: A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002;99:2712-2719.
28. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, de Block C, Seigneurin JM, de Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, and Chatenoud L: Insulin needs after CD3-antibody therapy in newonset type 1 diabetes. N Engl J Med 2005;352:2598-2608. (Pubitemid 41007846)
29. Targan S, Salzberg BA, and Mayer L: A phase I-II study: multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with IV steroids. Gastroenterology 2005;128: A-75.
30. D'Haens G, and Daperno M: Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2006;8:506-512.
31. Friend PJ, Hale G, Chatenoud L, Rebello P, Bradley J, Thiru S, Phillips JM, and Waldmann H: Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999;68:1632-1637.
32. Li B, Wang H, Dai J, Ji J, Qian W, Zhang D, Hou S, and Guo Y: Construction and characterization of a humanized antihuman CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology 2005;116:487-498.
33. Gaston RS, Deierhoi MH, Patterson T, Prasthofer E, Julian BA, Barber WH, Laskow DA, Diethelm AG, and Curtis JJ: OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney Int 1991;39:141-148.
34. Chatenoud L, Primo J, and Bach JF: CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997;158:2947-2954.
35. Bisikirska B, Colgan J, Luban J, Bluestone JA, and Herold KC: TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+ CD25+ Tregs. J Clin Invest 2005;115:2904-2913.
36. Lange H, Muller TF, Ebel H, Kuhlmann U, Grebe SO, Heymanns J, Feiber H, and Riedmiller H: Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Transplant Int 1999;12:2-9.
37. Bas J, Mestre M, Grino JM, Massip E, Castelao AM, Romeu A, Gonzalez L, Valls A, and Buendia E: In vitro donorspecific hyporesponsiveness and T cell subsets in renal allograft recipients. Allergol Immunopathol (Madr) 1993;21:136-140.
38. Filaci G, Fravega M, Negrini S, Procopio F, Fenoglio D, Rizzi M, Brenci S, Contini P, Olive D, Ghio M, Setti M, Accolla RS, Puppo F, and Indiveri F: Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+ CD28-T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol 2004;65:142-156.
39. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, and Bluestone JA: Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1 (Ala-Ala). J Clin Invest 2003;111:409-418.
40. Popma SH, Griswold DE, and Li L: Anti-CD3 antibodies OKT3 and hOKT3gamma1 (Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecific T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells. Int Immunopharmacol 2005;5:155-162.
41. Li J, Davis J, Bracht M, Carton J, Armstrong J, Gao W, Scallon B, Fung R, Emmell E, Zimmerman M, Griswold DE, and Li L: Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody. Int Immunopharmacol 2006;6:880-891.
42. You S, Leforban B, Garcia C, Bach JF, Bluestone JA, and Chatenoud L: Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci USA 2007;104:6335-6340.